Patenting genes
Open accessAbstract
May slow down innovation, and delay availability of cheaper genetic tests
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There was an infamous patent dispute over the BRCA1 and BRCA2 genes.
“A good example is the infamous patent dispute over the BRCA1 and BRCA2 genes [147,148].”
From Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review (2026) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 6
- [1]Matthijs G, Halley D. European-wide opposition against the breast cancer gene patents. Eur J Hum Genet 2002;10: 783-5 [DOI] [PubMed] [Google Scholar]
- [2]European Patent Office. “Myriad/breast cancer” patent revoked after public hearing. Press release, 2004. www.european-patent-office.org/news/pressrel/2004_05_18_e.htm (accessed 18 May, 2004)
- [3]Cancer Research UK. Charities to make breast cancer (BRCA2) gene freely available across Europe. Press release, 2004. www.cancerresearchuk.org/news/pressreleases/breastcancergene_11feb04?version=1 (accessed 11 Feb 2004).
- [6]American College of Medical Genetics. Position statement on gene patents and accessibility of gene testing. http://genetics.faseb.org/genetics/acmg/pol-34.htm (accessed 3 Jun 2004). [DOI] [PubMed]
- [7]Sevilla C, Moatti JP, Julian-Reynier C, Eisinger F, Stoppa-Lyonnet D, Bressac-de Paillerets B, et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 2002;10: 599-606. [DOI] [PubMed] [Google Scholar]
- [8]Merz JF, Kriss AG, Leonard DG, Cho MK. Diagnostic testing fails the test. Nature 2002;415: 577-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
Cited by
Sorted by citations
Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review
Weiskirchen, R. (2026) · Medical Sciences · doi:10.3390/medsci14010025 · Cited by 4 · see citing works
- Authors
- Matthijs, G.
- Affiliations
- KU Leuven (BE)
- Corresponding author
- Matthijs, Gert
- ORCID
- Matthijs, Gert
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2004-12-09
- Volume
- 329
- Issue
- 7479
- Pages
- 1358-1360
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- PMC
- PMC535439
- OpenAlex
- W17808122
- Cited by
- 17
- References
- 0
- Citations by year
- 2026: 2 · 2016: 1 · 2013: 1 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Intellectual Property and Patents
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Law › Intellectual Property Law
- Keywords
- gene patents, genetic testing, innovation, intellectual property, genetic research
- MeSH terms
- Genes, Genetic Techniques, Genetics, Humans, Patents as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
